First clinical site now open for large trial testing seralutinib for PH-ILD
The first clinical site is now active for a global Phase 3 study that will evaluate Gossamer Bio’s therapy candidate seralutinib in people with pulmonary hypertension associated with interstitial lung disease (PH-ILD). Dubbed SERANATA, the study aims to enroll about 480 people with PH-ILD, ages 18 to 80. No…